All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Safety analysis finds venetoclax monotherapy is well tolerated in patients with R/R CLL

Sep 17, 2018

Bookmark this article

A comprehensive safety analysis of venetoclax monotherapy was published in Clinical Cancer Research on 12 June 2018 by Matthew Davids, Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, and colleagues. The study evaluated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) based on the 2008 iwCLL criteria.

Study Overview

  • The analysis evaluated venetoclax monotherapy (400 mg daily) in n = 350 patients receiving treatment until disease progression, unacceptable toxicity or study discontinuation from June 2011 to November 2016
    • Median age was 66 years (range, 28–85)
    • 60% of patients had del(17p) CLL and 48% had TP53 mutation
    • The median prior lines of therapy was 3 (range, 0–15)
    • Median duration of exposure to venetoclax was 16 months (range, 0–56)
  • Patients in the analysis were included from the phase-I M12-175 (NCT01328626), phase-II M13-982 (NCT01889168) or phase-II M14-032 (NCT02141282)

Key Findings

  • The most frequent adverse events (AEs) of any grade included; diarrhea (41%) and nausea (39%)
  • The most frequent AEs grade 3/4 included; neutropenia (37%), anemia (17%) and thrombocytopenia (14%)
  • The most common AEs grade ≥3 that were possibly related to venetoclax, as assessed by the investigator, included; neutropenia (30%), thrombocytopenia (8%) and anemia (7%)
  • 29 deaths were reported, 14 were due to disease progression
  • 11 patients reported tumor lysis syndrome (TLS)
  • 251 patients experienced infections, the most common was upper respiratory tract infection (25%), pneumonia (11%), nasopharyngitis (10%), and urinary tract infection (10%)

The authors found from this analysis that venetoclax monotherapy was well tolerated with patients with R/R CLL. They recommended that standardized ramp-up dosing and risk-adapted prophylaxis and monitoring can help prevent TLS risk.

  1. Davids M. Et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clinical Cancer Research. 2018 Jun 12. pii: clincanres.3761.2017. doi: 10.1158/1078-0432.CCR-17-3761. [Epub ahead of print]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox